Direxion Daily PLTR Bull 2X Shares (NASDAQ: PLTU)

에 대한 최신 뉴스 Direxion Daily PLTR Bull 2X Shares (NASDAQ:PLTU)

The Fund, under normal circumstances, invests at least 80 percent of its net assets (plus any borrowings for investment purposes) in the securities of PLTR and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to PLTR, consistent with the Funds investment objective. The financial instrument in which the Fund most commonly invests is swap agreements which are intended to produce economically leveraged investment results.

Dreyfus Govt Cash Man Ins

Dreyfus Trsy Prime Cash Mgmt - In 0 -

Goldman Sachs Fin Gov 465 Institut

Gs Financial Square Treasury Instruments Fund

Palantir Technologies Inc.

Direxion Daily PLTR Bull 2X Shares

trader ai7

Long Ideas

Specialty ETFs

New ETFs

Tech

Trading Ideas

ETFs

BRKD

BRKU

PLTD

PLTR

PLTU

디렉시온(Direxion)의 최신 출시 상품은 단기 트레이더들에게 새로운 기회를 제공한다: 버크셔 해서웨이(NYSE:BRK)와 팔란티어 테크놀로지스(NASDAQ:PLTR)에 연동된 단일 주식 레버리지 및 인버스 ETF이다. 이번 조치는 디렉시온의 틈새 제품군을 확대하여 시장 참가자들에게 주식 시장에서 가장 상징적인 복합기업과 가장 화제의 중심에 있는 기술 주식 중 하나에 투자할 수 있는 새로운 방법을 제공한다.

버크셔와 팔란티어 ETF들, 디렉시온 출시로 강력한 거래 옵션 추가

Outlines strong operational and financial performance driven by the Company's transformative strategy
Warns that Elliott's high-risk proposals are misleading, based on flawed analysis and threaten long-term shareholder value
Underscores the valuable skills and experiences Phillips 66's Board and nominees have to drive shareholder value creation, superior to those of Elliott's nominees
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) (the "Company") today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its upcoming Annual Meeting of Shareholders on May 21, 2025.
In conjunction with the presentation, Phillips 66 published two new videos that showcase the skills and experiences the Company's two new Board nominees, A. Nigel Hearne and Howard Ungerleider, would bring to the Board and how they would approach driving shareholder value as a potential Board member of Phillips 66.
The presentation and the videos are available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phillips66delivers.com&amp;esheet=54244480&amp;newsitemid=20250427721989&amp;lan=en-US&amp;anchor=www.phillips66delivers.com&amp;index=1&amp;md5=da7ce40342b0431b228bfc94fbd4636d">www.phillips66delivers.com</a>.
Highlights of the investor presentation include:
Phillips 66's proven strategy has driven, and will drive, outperformance for shareholders
<ul>
<li>Since Mark Lashier became President and CEO in 2022, Phillips 66 has delivered total shareholder returns of 67%1, significantly outperforming the S&amp;P 500 Energy Index by 45%1 and the Company's synthetic proxy peer median2 by 42%1</li>
<li>In under three years, Phillips 66 has taken significant action, including returning over $14 billion to shareholders through share repurchases and dividends, rationalization of Refining assets, $3.5 billion in non-core asset divestitures, and opportunistic Midstream expansion through the Pinnacle and EPIC NGL acquisitions3</li>
<li>Reduced Refining Adjusted Controllable Costs from $6.98/bbl in 2022 to $5.90/bbl4 in 2024 with a clear plan in place to further reduce costs and achieve $5.50/bbl by 20275</li>
<li>Phillips 66's transformative strategy is in its early innings and has significant room to deliver further value. This proven strategy will continue to drive long-term competitiveness in Refining, grow the NGL value chain, maintain the Company's advantaged position in Chemicals, optimize profitability across all assets, and deliver consistent, compelling returns
<ul>
<li>Phillips 66 has delivered Refining profitability on par with peers on a like-for-like basis, while outperforming them in overall Refining cost improvements since 2022 6. The Company remains focused on cost improvements with a focus on further enhancing market capture.</li>
<li>Compared to 2021, our projected Midstream Adjusted EBITDA (post EPIC NGL) has grown by $1.9 billion, driven by an incremental 18% Cash Return on Capital Invested7, with additional organic growth opportunities in the future</li>
<li>CPChem's global scale and feedstock advantages result in a self-funding joint venture with stable, growing distributions that is constructing two world-scale projects coming online in late 2026</li>
</ul>
</li>
</ul>
The Company's integrated model creates consistent and compelling long-term value for shareholders
<ul>
<li>Compared to the weighted proxy peer average, the Company's integrated model delivers higher returns for shareholders and lower volatility across cycles</li>
<li>Phillips 66's integrated structure creates $500 million in annual operating synergies8, as the Midstream business ensures reliable supply and integrated logistics for refineries and CPChem, ultimately improving flow assurance, feedstock quality, blending efficiency, and market flexibility</li>
<li>Since the spinoff in 2012, we have grown our dividend at a 15% CAGR.9 Our annual dividend paid has increased every year – a rare achievement in the energy sector, especially through economic and commodity cycles</li>
</ul>

News

Phillips 66 Files Investor Presentation Highlighting Strategy, Board Strength, and Path For Shareholder Value Creation

JP Morgan analyst Jeffrey Zekaukas downgrades Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Overweight to Neutral and lowers the price target from $112 to $76.

Downgrades

Price Target

Analyst Ratings

JP Morgan Downgrades Eastman Chemical to Neutral, Lowers Price Target to $76

Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.50 by 14 percent. This is a 52.89 percent decrease over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $540.47 million which missed the analyst consensus estimate of $552.05 million by 2.10 percent. This is a 17.07 percent decrease over sales of $651.70 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ARLP

Alliance Res Partners Q1 EPS $0.57 Beats $0.50 Estimate, Sales $540.47M Miss $552.05M Estimate

ADMA

ADMA Biologics Announces FDA Approval Of Its Yield Enhancement Production Process

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is looking for Q2 GAAP EPS of $3.33-$3.37 vs $3.45 analyst estimate..

Guidance

Roper Techs Sees Q2 GAAP EPS $3.33-$3.37 vs $3.45 Est

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) lowers FY2025 GAAP EPS guidance from $14.21-$14.46 to $13.72-$13.97 vs $14.19 analyst estimate..

Roper Techs Lowers FY2025 GAAP EPS Guidance from $14.21-$14.46 to $13.72-$13.97 vs $14.19 Est

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is looking for Q2 Adj EPS of $4.80-$4.84 vs $4.86 analyst estimate..

Roper Techs Sees Q2 Adj EPS $4.80-$4.84 vs $4.86 Est

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) raises FY2025 Adj EPS guidance from $19.75-$20.00 to $19.80-$20.05 vs $19.92 analyst estimate. Raises FY2025 sales outlook from $7.74 billion to $7.88 billion vs $7.74 billion estimate.

Roper Techs Raises FY2025 Adj EPS Guidance from $19.75-$20.00 to $19.80-$20.05 vs $19.92 Est; Raises FY2025 Sales Guidance from $7.74B to $7.88B vs $7.74B Est

Jefferies analyst Joe Dickstein initiates coverage on American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Buy rating and announces Price Target of $37.

Initiation

Jefferies Initiates Coverage On American Healthcare REIT with Buy Rating, Announces Price Target of $37

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building and leading the company's 50-country operating platform. As part of this planned transition, Dr. Backstrom will serve as a strategic advisor, working closely with the company's executive team and Board of Directors.
Scholar Rock also announced today the addition of three leaders with unparalleled experience and success in building global organizations focused on developing and commercializing life-changing therapies.
<ul>
<li>Akshay Vaishnaw, M.D., Ph.D., has been named President of R&amp;D; he was formerly President of Alnylam.</li>
<li>R. Keith Woods has been appointed Chief Operating Officer and will focus on evolving the organization into a fully integrated global enterprise; he was formerly COO of argenx.</li>
<li>Vikas Sinha is joining as Chief Financial Officer; he was formerly CFO of Alexion and ElevateBio.</li>
</ul>
"On behalf of the Board, we are deeply grateful to Jay for his leadership over the past three years - driving us through the highly successful apitegromab global Phase 3 program and now into the US and European regulatory processes for marketing authorization," said Mr. Hallal. "As Board Chair, I have been continuously collaborating with Jay to accelerate Scholar Rock's evolution into a global biotech leader. These efforts will be amplified by the immediate addition of Akshay, Keith and Vikas - three operators that have built and led some of the most successful biotech companies in our industry. Together, we are committed to realizing Scholar Rock's global ambitions to bring apitegromab to SMA patients around the world."
"It has been an honor to lead the incredible team at Scholar Rock over the past several years. I am very proud of all we have achieved - from advancing apitegromab through a successful, pivotal Phase 3 study and on the path to becoming a commercial company," said Dr. Backstrom. "With the BLA now accepted under priority review and the anticipated launch later this year, this is the right moment for our leadership transition. I'm grateful for the close partnership over the years with David and Akshay as board members, and I look forward to continuing our collaboration on behalf of the SMA community to bring our highly innovative apitegromab, the world's first muscle targeted treatment, to patients and families living with the impact of this severe and progressive disease."

Management

SRRK

Scholar Rock Names Vikas Sinha as CFO, Keith Woods as COO Amid Big Biotech Expansion Plans

Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported quarterly earnings of $4.78 per share which beat the analyst consensus estimate of $4.74 by 0.84 percent. This is a 8.39 percent increase over earnings of $4.41 per share from the same period last year. The company reported quarterly sales of $1.88 billion which beat the analyst consensus estimate of $1.82 billion by 3.20 percent. This is a 12.02 percent increase over sales of $1.68 billion the same period last year.

Roper Techs Q1 Adj. EPS $4.78 Beats $4.74 Estimate, Sales $1.88B Beat $1.82B Estimate

Canaccord Genuity analyst Edward Nash initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announces Price Target of $64.

CLDX

Canaccord Genuity Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $64

As trade tensions between the U.S. and China escalate, Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) may hold a critical advantage over rival Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) through its <a href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth">diversified global manufacturing network</a>.
What Happened: While smartphones are currently exempt from President Donald Trump&#8216;s reciprocal tariffs, which reached 145% on Chinese imports this month, analysts warn that additional semiconductor-specific tariffs are forthcoming, CNN <a href="https://edition.cnn.com/2025/04/22/tech/apple-samsung-iphone-china-trade-war/index.html">reported</a>. This disparity in manufacturing footprints could prove consequential.
Apple remains heavily dependent on China, with Wedbush Securities estimating 90% of iPhone production still occurs there despite some shifts to India. By contrast, Samsung closed its last phone factory in China in 2019, with approximately 90% of its smartphone production now based in Vietnam, according to Counterpoint Research.
&#8220;The advantage is, yes, that they&#8217;re not facing the whatever crazy number we are currently dealing with,&#8221; said Gerrit Schneemann, senior analyst for Counterpoint Research.
However, analysts remain skeptical this will translate to immediate market gains for Samsung. Tight <a href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth">brand loyalty among Apple users</a> and different market positioning — Samsung dominates lower-priced segments while Apple controls premium markets — could limit customer migration.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45031324/bitcoin-ethereum-dogecoin-drop-as-stock-futures-slide-willy-woo-says-all-dips-are-for-buying-with-btc-eyeing-all-time-highs">Bitcoin, Ethereum, Dogecoin Drop As Stock Futures Slide: Willy Woo Says &#8216;All Dips Are For Buying&#8217; With BTC Eyeing &#8216;All-Time Highs</a>
Why It Matters: Additionally, <a href="https://www.benzinga.com/25/04/45032214/analyst-questions-apples-reported-iphone-shift-to-india-amid-china-tariff-pressures-doesnt-solve-all-the-problems">Vietnam and India still face 10% tariffs under Trump&#8217;s plan</a>, meaning Samsung isn&#8217;t completely insulated from trade pressures.
The broader economic impact of tariffs also threatens consumer spending on electronics. &#8220;Daily necessities and essentials are going to be higher on the list then maybe a new or upgraded smartphone,&#8221; Schneemann noted.
Apple&#8217;s potential response includes accelerating its manufacturing shift to India, though analyst Craig Moffett of MoffettNathanson questions this strategy&#8217;s effectiveness since many components would still originate from China.
UBS analysts previously estimated an iPhone assembled in China could see price increases of up to $800 before smartphone <a href="https://www.benzinga.com/25/04/44973883/analysts-slash-aapl-stock-price-target-amid-anticipated-tariffs-supply-chain-concerns-a-lose-lose-choice">exemptions were announced</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Chamath Palihapitiya Says Nvidia Is Huawei&#8217;s &#8216;New Target&#8217; — A &#8216;National Champion&#8217; That Crushed Tech Giants With A &#8216;Low-End Disruptor&#8217; Strategy</a></li>
</ul>
Image Via Shutterstock

Equities

Markets

AAPL

SSNLF

As Tariffs Bite Apple, Samsung's Global Manufacturing Network Gains Edge In US-China Trade War

- NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –
DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton's proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026.

ETON

Eton Pharma Submits NDA To FDA For Proprietary Desmopressin Oral Solution ET-600; Anticipates Q1 2026 Launch After 10-month Review

Scholar Rock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srrk#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David
Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building and leading the company's 50-country operating platform. As part of this planned transition, Dr. Backstrom will serve as a strategic advisor, working closely with the company's executive team and Board of Directors. Scholar Rock also announced today the addition of three leaders with unparalleled experience and success in building global organizations focused on developing and commercializing life-changing therapies. Akshay Vaishnaw, M.D., Ph.D., has been named President of R&amp;D; he was formerly President of Alnylam. R. Keith Woods has been appointed Chief Operating Officer and will focus on evolving the organization into a fully integrated global enterprise; he was formerly COO of argenx. Vikas Sinha is joining as Chief Financial Officer; he was formerly CFO of Alexion and ElevateBio. "On behalf of the Board, we are deeply grateful to Jay for his leadership over the past three years - driving us through the highly successful apitegromab global Phase 3 program and now into the US and European regulatory processes for marketing authorization," said Mr. Hallal. "As Board Chair, I have been continuously collaborating with Jay to accelerate Scholar Rock's evolution into a global biotech leader. These efforts will be amplified by the immediate addition of Akshay, Keith and Vikas - three operators that have built and led some of the most successful biotech companies in our industry. Together, we are committed to realizing Scholar Rock's global ambitions to bring apitegromab to SMA patients around the world." "It has been an honor to lead the incredible team at Scholar Rock over the past several years. I am very proud of all we have achieved - from advancing apitegromab through a successful, pivotal Phase 3 study and on the path to becoming a commercial company," said Dr. Backstrom. "With the BLA now accepted under priority review and the anticipated launch later this year, this is the right moment for our leadership transition. I'm grateful for the close partnership over the years with David and Akshay as board members, and I look forward to continuing our collaboration on behalf of the SMA community to bring our highly innovative apitegromab, the world's first muscle targeted treatment, to patients and families living with the impact of this severe and progressive disease."

Scholar Rock Names Chair David Hallal as New CEO Taking Over From Jay Backstrom

BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent. This is a 21.88 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $255.41 million which missed the analyst consensus estimate of $263.57 million by 3.10 percent. This is a 5.66 percent increase over sales of $241.73 million the same period last year.

BankUnited Q1 EPS $0.78 Beats $0.74 Estimate, Sales $255.41M Miss $263.57M Estimate

Chardan Capital analyst James McIlree reinstates VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) with a Buy and lowers the price target from $13 to $5.5.

Chardan Capital Reinstates Buy on VinFast Auto, Lowers Price Target to $5.5

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (SOC) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (SMIs) in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models. The results from these preclinical studies were shared in a poster presentation at the 2025 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois.
Key findings from the studies included:
<ul>
<li>ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), induced significantly greater tumor growth inhibition compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination.</li>
<li>ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin) resulted in tumor regressions and demonstrated significantly stronger tumor growth inhibition compared with each agent alone.</li>
<li>In preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression.</li>
<li>ARV-393 in combination with investigational small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior tumor growth inhibition compared with each agent alone, with tumor regressions in all mice treated with the combinations.</li>
</ul>

ARVN

Arvinas Reports Preclinical Results for New Lymphoma Drug Combo at Cancer Research Meeting

Telsey Advisory Group analyst Dana Telsey maintains ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) with a Outperform and raises the price target from $3 to $6.

TDUP

Telsey Advisory Group Maintains Outperform on ThredUp, Raises Price Target to $6

U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies.
The markets are jittery ahead of a packed earnings week, with four of the &#8220;Mag 7&#8221; — Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) — alongside several other heavy-hitters, set to release their results over the next few days.
Investors will be closely watching the results of Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>), Domino&#8217;s Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), and NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) on Monday to set the tone for the rest of this week.
U.S. 10-Year Treasuries are at 4.26%, while the 2-Year Treasuries are at 3.77%. The CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows the markets pricing a 93.1% likelihood of interest rates remaining unchanged during the FOMC meeting, the first week of May, marking a decline from Friday, at 95.3%.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Futures</td>
<td class="has-text-align-center" data-align="center">Change (+/-)</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">-0.03%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">-0.13%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq 100</td>
<td class="has-text-align-center" data-align="center">-0.11%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">-0.32%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100 index, are both down 0.27% and 0.28% in Monday&#8217;s pre-market trading, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;138z7gr&#x2A;_gcl_au&#x2A;MjA5Njc0MjY1My4xNzQwODM2NTUw&#x2A;_ga&#x2A;R1MxLjEuMTc0NDY0ODA3Mi4yLjAuMTc0NDY0ODA3NS4wLjAuMA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTgyOTMzMy4xLjEuMTc0NTgyOTYyMy4wLjAuMA..">Benzinga Pro</a> data.
Cues From Last Week:
The markets were aided by strong earnings performances by AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), but disappointing performances by Aon PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) and HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) weighed on the rally. 
Consumer Sentiment Report (Final), released on Friday, highlighted an 8% slip in sentiments compared to the prior month, as uncertainties continue to persist, having an impact on consumer purchasing decisions.
The S&amp;P 500 capped off the week on a high note on Friday, led by communications, consumer discretionary, healthcare, and technology. Financials, consumer staples, real estate, and materials were, however, in the red during the day.
As of Friday, the Nasdaq 100 is down 12.5% from its high of 22,222.61 points, the S&amp;P 500 is down 10.1% from 6147.43 points, and the Dow Jones Industrial Average is down 11% from 45,073.63 points.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Index</td>
<td class="has-text-align-center" data-align="center">Performance (+/-)</td>
<td class="has-text-align-center" data-align="center">Value</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq Composite</td>
<td class="has-text-align-center" data-align="center">1.26%</td>
<td class="has-text-align-center" data-align="center">17,382.94</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">0.74%</td>
<td class="has-text-align-center" data-align="center">5,525.21</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">0.05%</td>
<td class="has-text-align-center" data-align="center">40,113.50</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">0.00014%</td>
<td class="has-text-align-center" data-align="center">1,957.62</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Analysts are rather upbeat going into this earnings week, with several leading experts pointing towards optimistic consensus estimates as a sign that the markets are yet to price in a recession or even a slowdown, for that matter, according <a href="https://www.ft.com/content/4aa1d7d7-4162-4e25-a6d6-a174a9626681">to</a> a report by FT. 
According to Daniel Von Ahlen of TS Lombard, &#8220;The information derived from risk assets doesn't even suggest markets reckon a mild slowdown will take shape this year.&#8221;
Peter Berezin, a chief global strategist at BCA Research, says that &#8220;typically earnings estimates decline during even mild recessions,&#8221; but the markets are now pricing a 10% earnings growth over the next twelve months, and that&#8217;s of &#8220;last year's peak profit margins no less,&#8221; he says.
See Also: <a href="https://www.benzinga.com/general/25/04/45004194/dave-ramsey-calls-social-security-a-4-return-but-this-wealth-expert-says-thats-a-dangerous-oversimplification-that-could-cost-thousands" target="_blank" rel="noreferrer noopener">Dave Ramsey Calls Social Security A ‘-4% Return' —But This Wealth Expert Says That's A Dangerous Oversimplification That Could Cost Thousands</a>
Upcoming Economic Data: 
There is no major economic data being released on Monday.
Stocks In Focus:
<ul>
<li>Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is set to release its earnings after the markets close on Monday, and the stock is up 2% in pre-market trade, with analysts expecting $2.4 billion in revenue. </li>
<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is up 0.41% in pre-market trade, as investors await its quarterly earnings release. Analysts expect $6.1 billion in revenue and $1.59 per share in earnings. </li>
<li>Cadence Design Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is largely flat pre-market, up by just 0.03%, with the company set to announce its earnings after markets close on Monday. Analysts expect $1.2 billion in revenue and earnings per share of $1.50. </li>
<li>Roper Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is an industrial conglomerate that is scheduled to announce its first quarter results before the opening bell. Consensus estimates expect $1.9 billion in revenue and $4.74 per share in earnings. </li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is up 0.59% pre-market and is set to announce its earnings after markets close. Analysts expect $2.8 billion in revenue and $2.18 per share in earnings.</li>
</ul>
Commodities, Gold And Global Equity Markets
Crude oil futures are trading down 0.46% during the early New York session, at $62.73 per barrel.
Gold Spot U.S. Dollar continued its decline, and is down 1.72% on Monday, trading at 3,275.24 per ounce, down from its record high of $3.400 per ounce last week. The U.S. Dollar Index (DXY) is up 0.03%, trading at 99.626.
Asian markets were mixed on Monday, with Japan&#8217;s Nikkei 225 Index ending up 0.38%, South Korea&#8217;s Kospi up 0.10%, followed by Indian, Australian, and New Zealand indexes edging up, with the only laggards being China&#8217;s Shanghai and Shenzhen. European markets are all up in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44942921/national-social-security-month-returns-under-trump-as-ssa-cites-1-billion-in-savings-and-vows-to-serve-the-people-by-ending-dei-contracts-and-replacing-bureaucracy-with-customer-service" target="_blank" rel="noreferrer noopener">National Social Security Month Returns Under Trump As SSA Cites $1 Billion In Savings, Vows To ‘Serve The People'</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Futures

ABBV

AMZN

CDNS

MSFT

NXPI

WELL

US Stock Futures Fall As Markets Brace For Earnings From Microsoft, Meta, Apple And Apple This Week: 'Earnings Estimates Don't Signal A Recession' Says Leading Analyst

Press Releases

Direxion Unveils Berkshire Hathaway and Palantir Single Stock Leveraged and Inverse ETFs

Screenshot 2025-01-21 at 6.47.03 PM

PYPL

Riding The Bull Or Betting On The Bear: Direxion&#39;s 2X &amp; -1X ETFs For Berkshire Hathaway And Palantir Traders

디렉시온(Direxion)의 최신 출시 상품은 단기 트레이더들에게 새로운 기회를 제공한다: 버크셔 해서웨이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)와 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)에 연동된 단일 주식 <a href="https://www.benzinga.com/topic/leveraged-etfs">레버리지 및 인버스 ETF</a>이다.
이번 조치는 디렉시온의 틈새 제품군을 확대하여 시장 참가자들에게 주식 시장에서 가장 상징적인 복합기업과 가장 화제의 중심에 있는 기술 주식 중 하나에 투자할 수 있는 새로운 방법을 제공한다.
<h2 class="wp-block-heading">트레이더의 놀이터</h2>
전설적인 투자자 워런 버핏이 이끄는 버크셔 해서웨이는 매우 강력한(high-octane) 트레이딩을 위해 가장 먼저 생각나는 주식은 아니다. 체계적이고 장기적인 초점으로 알려진 버크셔의 포트폴리오는 &#8220;느리고 꾸준하게&#8221;의 전형이다. 하지만 디렉시온의 새로운 제공 상품인 Direxion Daily BRKB Bull 2X Shares(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKU#NASDAQ">BRKU</a>) (2배 일일 강세 노출)와 Direxion Daily BRKB Bear 1X Shares(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKD#NASDAQ">BRKD</a>) (1배 일일 약세 노출)는 월스트리트에서 가장 안정적인 이름 중 하나에 추가적인 흥미를 가져올 것을 약속한다.
&#8220;디렉시온의 ETF 산업에서의 지속적인 혁신에 대한 헌신은 제가 팀에 합류한 여러 가지 이유 중 하나이다&#8221;라고 디렉시온의 CEO인 더글라스 욘스(Douglas Yones)가 말했다.
반면에, 팔란티어는 이러한 종류의 거래에 특별히 적합한 것처럼 보인다. 정부 계약, 인공지능(AI) 열풍 그리고 증가하는 상업적 입지로 급등한 주식인 팔란티어는 이미 소매 트레이더들의 주목을 받고 있다. Direxion Daily PLTR Bull 2X Shares(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTU#NASDAQ">PLTU</a>) (2배 일일 강세 노출)와 Direxion Daily PLTR Bear 1X Shares(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTD#NASDAQ">PLTD</a>) (1배 일일 약세 노출)와 함께, 디렉시온은 팔란티어의 높은 변동성과 열정적인 팬층이 행동으로 이어질 것이라고 예상하고 있다.
<h2 class="wp-block-heading">왜 단일 주식 ETF인가?</h2>
단일 주식 ETF는 마음이 약한 사람이나 매수-보유 투자자에게 적합하지 않다. 이러한 ETF는 본래 일일 변동을 증폭시켜 변동성을 선호하는 트레이더들을 위한 도구가 된다. 전통적인 ETF와 달리, 이러한 상품은 개별 주식을 추적하여 분산 투자라는 안전망을 건너뛴다.
디렉시온은 이 제품들이 단기 사용을 목적으로 한다고 강조하지만, 손실이 증폭될 수 있는 잠재력은 그 위험성을 강조한다.
추가 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%84%ED%95%8F-%EC%A7%80%EC%88%98-%EB%8B%B7%EC%BB%B4-%EB%B2%84%EB%B8%94-%EB%8B%B9%EC%8B%9C-140%EC%98%80%EB%8A%94%EB%8D%B0-%EC%A7%80%EA%B8%88-200-%EC%9D%B4%EC%83%81%EC%9C%BC%EB%A1%9C-%EC%98%AC/" target="_blank" rel="noopener">워런 버핏은 &#8216;불장난&#8217;이라고 명명된 지표가 140%에 도달했을 때 경고 — 오늘날 200%가 넘는다: 시장 하락이 임박했나요?</a>
<h2 class="wp-block-heading">버핏의 느린 차선과 팔란티어의 고속도로</h2>
이번 출시에서 버크셔와 팔란티어의 대조는 오늘날 거래 환경의 다양성을 강조한다. 버크셔는 오래된 수호세력으로, 검증된 것이지만 버핏의 지침에 따른 일일 감정 변화에 면역이 아니다. 반면 팔란티어는 AI 꿈과 고위험 파트너십에 의해 촉진되는 추측으로 번성한다.
이 ETF는 테슬라와 애플와 같은 다른 이름들을 겨냥한 디렉시온의 22개의 단일 주식 레버리지 및 인버스 펀드의 보다 넓은 제품군에 추가된다.
BRKU, BRKD, PLTU 또는 PLTD가 이 경쟁 시장에서 틈새를 확보할 수 있을지는 두고 봐야겠지만, 한 가지는 분명하다: 이들 제품은 시장에서 가장 주목받는 두 주식에 대한 거래에 새로운 복잡성을 제공한다.
<h2 class="wp-block-heading">신중하게 진행</h2>
이렇게 거래에 뛰어들고 싶은 분들에게 한 가지 조언: 거래하는 내용을 아는 것이 중요하다. 레버리지 ETF는 높은 위험 도구이며, 단순히 설정하고 잊어버릴 수 있는 투자가 아니다. 이 펀드는 레버리지 투자 결과를 추구할 때의 위험을 깊이 이해하는 사람들을 위한 것이다.
트레이더들이 버크셔의 지혜나 팔란티어의 변동성을 활용하기 위해 이러한 도구를 받아들일까? 이는 오직 시장만이 답할 수 있는 베팅이다.

다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42387962/palantir-scores-368-million-deal-with-ussocom-to-lead-ai-powered-mission-command">팔란티어, 3억 6천 8백만 달러 규모의 USSOCOM 계약을 따낸 후 급등 &#8211; 무슨 일이 일어나고 있나?</a></li>
</ul>
이미지는 Midjourney를 통해 인공지능으로 생성되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Direxion Daily PLTR Bull 2X Shares

뉴스

에 대한 최신 뉴스 Direxion Daily PLTR Bull 2X Shares (NASDAQ:PLTU)

목요일, 12월 12, 2024

뉴스

파트너 / 기고자

벤징가 글로벌